The United Kingdom has struck a deal with the United States under which British-made medicines, medical-device components and pharmaceutical ingredients will enter the U.S. tariff-free for at least three years — in return for a substantial increase in what the national health service pays for certain drugs.

The agreement was announced by U.S. trade authorities earlier this week.

Under the terms, the model used by the health technology appraisal body will be relaxed — the cost-effectiveness threshold per “quality-adjusted life year” will rise, and net prices paid by the public health service for new patented medicines will increase by 25 per cent.

Rebates that drug companies currently pay back when usage exceeds a quota will be capped at 15 per cent, easing pressure on manufacturers.

Officials describe the changes as the first major increase to medicine pricing in more than two decades.

U.K. ministers contend the deal balances patient access and national interests: raising the threshold will allow previously rejected but potentially life-saving treatments — for conditions such as cancer or rare diseases — to be funded by the public health service.

The increased drug budget is also intended to bolster the country’s life-sciences sector, stabilise exports to the U.S., and protect thousands of jobs tied to pharmaceutical manufacturing and research.

From the U.S. perspective, the agreement undercuts the need for punitive import tariffs that had been threatened on branded foreign drugs, a core demand of President Donald Trump’s trade agenda.

U.S. officials argue that raising medicine prices in countries such as the U.K. ends what they have described as an unfair subsidy by American consumers, and helps equalise global pharmaceutical pricing.

The deal has drawn mixed reactions.

Pharmaceutical companies welcomed the move for offering price certainty and encouraging renewed investment.

Patient advocates and some health-economics experts, however, have warned that shifting increased costs onto the public health system could strain budgets, particularly as hospital services already face funding pressures.

The government acknowledges the need to identify long-term financing but maintains the reforms are designed to preserve access and competitiveness without undermining core care priorities.

With this agreement, the U.K. becomes the first country to secure a zero-tariff guarantee on pharmaceuticals under the Trump administration’s tariff threat regime, in exchange for structural changes to how public drug funding is managed.

The terms are set to come into effect immediately, offering a temporary reprieve for exporters and patients alike while reshaping Britain’s medicines procurement framework.